AIM ImmunoTech Advances DURIPANC Trial with Final Dosing Milestone
OCALA, Fla., Aug. 3, 2026 AIM ImmunoTech Inc. announced that the final patient has received the last protocol-defined dose...
Biomarkers
Advertisement
FDA Licenses First-Ever Freeze-Dried Plasma Product in U.S.
SILVER SPRING, Md., July 29, 2026 The U.S. Food and Drug Administration (FDA) has licensed Ezplaz Freeze Dried Plasma...
Leads Biolabs Gains China IND for Opamtistomig in mCRC
NANJING, China, August 3, 2026 Leads Biolabs announced that the Center for Drug Evaluation (CDE) of China’s National Medical...
Avenda Health Expands Unfold AI Across Prostate Cancer Care
CULVER CITY, Calif., July 28, 2026 Avenda Health announced that its FDA-cleared Unfold AI platform is now being used...
10x Genomics, CHUV Advance Precision Cancer Diagnostics
PLEASANTON, Calif., July 29, 2026 10x Genomics has entered a multi-year research collaboration with Lausanne University Hospital (CHUV) to...
Advertisements
Medicus Pharma Receives UAE IND Authorization for PRECISION-E2 Study
PHILADELPHIA, July 31, 2026 Medicus Pharma Ltd. announced that the United Arab Emirates (UAE) Department of Health – Abu...
ProMIS Neurosciences Reports Positive Phase 1b PMN310 Interim Data
CAMBRIDGE, Mass., July 28, 2026 ProMIS Neurosciences Inc. announced positive blinded six-month interim safety and biomarker data from the...
City of Hope Launches Phase 2 Lung Cancer Biomarker Trial
LOS ANGELES, July 21, 2026 City of Hope has launched the national Phase 2 IMMUNO-BIOMAP clinical trial to better...
Eurofins Viracor Expands Cytokine Testing Portfolio
LENEXA, Kan., July 16, 2026 Eurofins Viracor has expanded its immunology testing portfolio with the launch of three new...
ProMIS Reports First Human PMN310 Evidence
CAMBRIDGE, Mass., July 14, 2026 ProMIS Neurosciences presented the first human evidence that its investigational Alzheimer’s disease therapy PMN310...
Advertisement
